Company Profile

Genor Biopharma Holdings Ltd is a company primarily engaged in the biopharmaceuticals business. The Companyâ€™s main business is engaged in the discovery, development and commercialization of biopharmaceutical products for human use. The Companyâ€™s product pipelines include GB491 (Lerociclib), GB261, GB263T and other products, covering disease fields such as breast cancer, lung cancer, gastrointestinal tumors, and blood tumors. The Company mainly conducts its business in the domestic market.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-31 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-02-10	2.970 $	+7.61%	1,283,096
26-02-09	2.760 $	-3.16%	2,202,500
26-02-06	2.850 $	+7.55%	3,624,500
26-02-05	2.650 $	+1.15%	1,462,000
26-02-04	2.620 $	+1.16%	2,483,500

Delayed Quote Hong Kong S.E., February 10, 2026 at 03:09 am

More quotes

Market Closed - Hong Kong S.E. Other stock markets 03:09:14 2026-02-10 EST			5-day change	1st Jan Change
2.970 ^HKD	+7.61%		+14.67%	-1.00%

02-08	Edding Genor Begins Dosing in Phase 2 Trial of EDP167	MT
02-03	Genor Biopharma Changes Name to Edding Genor Group	MT

02-08	Edding Genor Begins Dosing in Phase 2 Trial of EDP167	MT
02-03	Genor Biopharma Changes Name to Edding Genor Group	MT
01-28	Edding Genor Group Holdings Limited commences an Equity Buyback Plan for 52,060,469 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2025.	CI
12-30	Genor Biopharma Holdings Limited will Change its Name to Edding Genor Group Holdings Limited	CI
12-29	Genor Biopharma Completes Reverse Merger Transaction With Edding Group	MT
12-29	Edding Group Company Limited completed the acquisition of Genor Biopharma Holdings Limited in a reverse merger transaction.	CI
12-09	Genor Biopharma's Breast Cancer Drug Included in China's Reimbursement Drug List	MT
12-08	Genor Biopharma Holdings Limited Announces the Inclusion of Lerociclib in China's National Reimbursement Drug List	CI
12-04	Edding Genor Group Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-09-17	Metalpha Technology Holding Limited Announces Appointment of Ms. Isabella He as Its New Head of Institutional & IR, Effective September 22, 2025	CI
25-08-29	Genor Biopharma Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-01	Genor Biopharma Partner Advances in Autoimmune Disease Drug Trial	MT
25-06-30	Candid Therapeutics, Inc. Announces Advances in Its In-Licenced Novel T-Cell Engager into Autoimmune Diseases for Clinical Evaluation	CI

02-08	Edding Genor : EDG Announced EDP167 has successfully completed the first subject dosing in its Phase II clinical trial	PU
24-08-29	Genor Biopharma : Releases Its Interim Results for 2023	PU
24-08-05	Genor Biopharma : GB261(CD3/CD20) goes global	PU
24-05-23	G1 THERAPEUTICS AND DEIMOS BIOSCIENCES ANNOUNCE GLOBAL LICENSE AGREEMENT FOR LEROCICLIB FOR RADIOPROTECTIVE USES	AQ

1 day	+7.61%
1 week	+14.67%
Current month	+18.80%
1 month	+23.75%
Current year	-1.00%

Edding Genor Group Holdings Limited Stock

Equities

6998

KYG3871A1004

Biotechnology & Medical Research

Chart: Edding Genor Group Holdings Limited

Latest news: Edding Genor Group Holdings Limited

Press Releases: Edding Genor Group Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: Edding Genor Group Holdings Limited

Bio Therapeutic Drugs

Company Profile

Quotes

1 week	2.52	3
1 month	2.25	3
Current year	2.25	3.14
1 year	2.25	3.19
3 years	2.25	3.19
5 years	2.25	3.19
10 years	2.25	3.19

Manager	Title	Age	Since
Feng Guo CEO	Chief Executive Officer	56	2020-04-15
Chengyi Weng DFI	Director of Finance/CFO	46	2024-09-11
Tong Li CTO	Chief Tech/Sci/R&D Officer	57	2020-07-30

Director	Title	Age	Since
Guan Hao Fung BRD	Director/Board Member	61	2020-06-11
Wen Chen BRD	Director/Board Member	57	2020-06-19
Yi Liu BRD	Director/Board Member	37	2022-07-28

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
EDDING GENOR GROUP HOLDINGS LIMITED	+7.61%	+14.67%	-	-	708M
ARGENX SE	-0.43%	-2.78%	+10.29%	+100.52%	51.1B
WUXI APPTEC CO., LTD.	+0.89%	+5.90%	+69.68%	+8.08%	42.55B
INSMED INCORPORATED	-0.21%	-2.88%	+87.04%	+653.73%	31.89B
BIONTECH SE	+3.49%	+1.34%	-6.18%	-21.49%	27.69B
WUXI BIOLOGICS (CAYMAN) INC.	+4.65%	+8.22%	+83.58%	-38.00%	20.25B
GENMAB A/S	+0.18%	-7.87%	+41.28%	-28.39%	18.95B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.29%	+8.86%	+141.15%	-	12.51B
AKESO, INC.	+3.93%	+4.76%	+63.75%	+137.53%	11.99B
EXELIXIS, INC.	+0.11%	+2.66%	+31.27%	+150.00%	11.83B
Average	+2.45%	+1.32%	+57.98%	+120.25%	22.95B
Weighted average by Cap.	+1.35%	-0.35%	+50.14%	+128.79%